BioChem Pharma Receives Patent For Lamivudine

14 July 1996

- BioChem Pharma has announced that it has received a US protection patent covering its once-daily, oral treatment lamivudine for chronic hepatitis B, until 2013. It has already received similar patents in Australia, Europe, Asia, and South Africa, with several others pending. Currently in Phase III clinical trials, it is expected that marketing applications will be filed in 1997. Lamivudine is also in trials as a once-daily oral pre- and post-transplant treatment for patients in end-stage liver disease, and who require a liver transplant as a result of chronic hepatitis B.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight